B Braun Medical has rolled out a new formulation of one of the nation’s most widely used injectable antibiotics. This marks the latest expansion of the company’s smart infusion and pain-management portfolio.

The global med-tech giant has launched Piperacillin and Tazobactam in its ready-to-activate DUPLEX Drug Delivery System. The antibiotic—now offered in 2.25 g/50 mL, 3.375 g/50 mL and 4.5 g/100 mL doses.

The announcement comes on the heels of B Braun’s Nurse Approved Certification for the drug in the DUPLEX system, along with the company’s full IV solutions line and plastic irrigation containers. The designation highlights a growing focus on usability and nursing workflow, underscoring the company’s push to streamline medication preparation at the bedside.

DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation. Providers fold, squeeze and shake the container to mix the dose—a method the company says cuts nearly four minutes from the preparation process and saves significant labor time compared with both the Baxter Mini-Bag Plus system and traditional compounding.

The closed system is also engineered to reduce contamination risks and prevent dosing errors, lowering the likelihood of medication mistakes by 54% through fewer process steps.

“The launch of Piperacillin and Tazobactam in the DUPLEX Drug Delivery System reinforces B. Braun's commitment to supporting healthcare professionals with ready-to-activate antibiotic options,” said Ellen Menard, Corporate Vice President, Marketing Pharma at B. Braun Medical.

“This product is designed to help reduce waste, save space and streamline preparation and administration—key advantages for busy pharmacy and nursing teams administering high-demand antibiotics.”

DUPLEX requires no thawing, can be stored at room temperature or in automated dispensing cabinets, and is positioned as a contamination-reducing alternative for hospitals managing high-volume antibiotic use.

The product is one of several injectable drugs B Braun plans to introduce in the US in the coming years as it works to broaden its portfolio and meet rising demand for essential medications, the company said.